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The metastatic progression of malignant tumour requires the
proteolytic degradation of extracellular matrix components such as
type IV collagen, laminin and proteoglycans. Matrix metallopro-
teinases (MMPs) play important roles in the extracellular matrix
degradation; especially the expression of MMP-2/gelatinase A
(72-kDa type IV collagenase) correlates closely with the invasive
and metastatic phenotype of tumour cell in vivo (Pyke et al, 1992;
Stearns and Wang, 1993; Stetler-Stevenson et al, 1993). MMP-2 is
biosynthesized as a proenzyme (proMMP-2) as well as other
MMPs, and the proteolytic cleavage of propeptide in the zymogen
is essential to express enzymic activity in vitro (Okada et al, 1990;
Birkedal-Hansen et al, 1993; Itoh et al, 1995). Concerning the acti-
vation of proMMPs in vivo, MMP-3/stromelysin-1 is identified as
an endogenous activator for proMMP-1/interstitial procollagenase
and proMMP-9/progelatinase B (Ito and Nagase, 1988; Ito et al,
1991; Ogata et al, 1992), but not for proMMP-2 (Okada et al,
1990). Baramova et al (1997) and Mazzieri et al (1997) reported
the involvement of plasminogen activator/plasmin system in
proMMP-2 activation. Recently, membrane type-MMPs, MT1-
MMP (Sato et al, 1994), MT2-MMP (Will and Hinzmann, 1995),
MT3-MMP (Takino et al, 1995) and MT4-MMP (Puente et al,
1996) have been discovered and reported to specifically activate
proMMP-2 on the cell surface. Furthermore, increased expression
of MT1-MMP has been shown to correlate with proMMP-2 acti-
vation in human malignant tumours in vivo (Yamamoto et al,
1996; Ueno et al, 1997). Thus, MT1-MMP is considered to be a
specific in vivo activator for proMMP-2.
The activation of proMMP-2 is induced by concanavalin A and
12-O-tetradecanoylphorbol 13-acetate in human fibroblasts and
human fibrosarcoma HT-1080 cells respectively (Ward et al, 1991;
Strongin et al, 1993). Lohi et al (1996) also reported that 12-O-
tetradecanoylphorbol 13-acetate and concanavalin A significantly
induce the expression of MT1-MMP in HT-1080 cells and human
embryonic lung fibroblasts. On the other hand, Seltzer et al (1994)
reported that b1 integrin receptor, possibly a2b1 augments the
conversion of 72-kDa proMMP-2 to 62-kDa active form in human
fibroblasts cultured in collagen lattices. In addition, calcium
ionophores inhibit the phorbol ester-induced proMMP-2 activation
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Summary Matrix metalloproteinase 2 (MMP-2)/gelatinase A plays an important role in tumour invasion and metastasis. Since MMP-2 is
secreted as an inactive form (proMMP-2) from tumour and neighbouring stroma cells, the activation process is necessary to express the
enzymic activity for degradation of extracellular matrix components. We herein reported that the activation of proMMP-2 was induced in
human squamous carcinoma cells co-cultured with normal human dermal fibroblasts. When A431 cells were co-cultured with human
fibroblasts at various cell ratios, 72-kDa proMMP-2 was converted to a 62-kDa active form through the appearance of a 64-kDa intermediate.
The activation of proMMP-2 by co-culture was also observed in other carcinoma cell lines, HSC-4 and SAS, but not in normal human
keratinocytes. We characterized by in vitro invasion assay that A431 cells in co-culture preferentially invaded through Matrigel and the
increased invasive activity was inhibited by exogenously adding tissue inhibitor of metalloproteinases 2. The augmented proMMP-2 activation
by co-culture was achieved by the increase in membrane type 1-MMP (MT1-MMP) production along with that of its mRNA level. The
predominant appearance of MT1-MMP was immunologically observed in A431 cells, but not human fibroblasts of the co-culture. Furthermore,
epidermal growth factor (EGF) enhanced the co-culture-mediated proMMP-2 activation by increasing the production and gene expression of
MT1-MMP, and thereby tumour invasive activity was further augmented. These results suggest that the cell–cell contact between carcinoma
cells and normal fibroblasts enhances the production of MT1-MMP followed by sequential activation of proMMP-2 on the tumour cell surface,
which may be closely implicated in tumour invasion in vivo.
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antagonists accelerate the proMMP-2 activation in human fibro-
blasts (Ito et al, 1998), but possible in vivo cellular mechanisms
controlling the production of MT-MMPs and the activation of
proMMP-2 remain unclear.
In the present study, we demonstrated that the activation of
proMMP-2 was induced by co-culture of human carcinoma cells
and normal human fibroblasts and thereby in vitro tumour invasive
activity was accelerated. The augmentation of proMMP-2 activa-
tion by the co-culture was associated with the predominant
increase in MT1-MMP production on carcinoma cells.
MATERIALS AND METHODS
Cell lines and cell culture conditions
Human epidermoid squamous carcinoma cell line, A431 (RIKEN
Cell Bank, Ibaraki, Japan), human oral squamous carcinoma cell
lines, HSC-4 and SAS (Health Science Research Resources Bank,
Osaka, Japan) and normal human dermal fibroblasts (Sato et al,
1997) were cultured in Dulbecco’s modified Eagle medium
(DMEM) (Life Technologies, Inc., Grand Island, NY, USA)
supplemented with 10% (v/v) fetal bovine serum (BioWhittaker,
Walkersville, MD, USA), 200 units ml–1 of penicillin and
200 mg ml–1 of streptomycin until confluence. Human epidermal
keratinocytes (Kyokuto Pharmaceutical Industrial Co., Tokyo,
Japan) were cultured as described previously (Sato et al, 1997).
For co-culture experiments, human dermal fibroblasts were first
seeded at 3.5 ´ 104 cells cm–2 in 24-well culture plates or 100-mm
diameter dishes and grown to confluence. The cells from three
wells or dishes were removed with 0.25% (w/v) trypsin – 0.02%
(w/v) EDTA/Ca2+ and Mg2+-free phosphate-buffered saline (PBS
(–)) and the number of cells were determined. Based on the
number of cells, carcinoma cells or keratinocytes as normal epithe-
lial cells were placed on the confluent monolayer culture of fibrob-
lasts at various cell ratios and allowed to attach for 24 h. After
24-h incubation, the cells were washed with the serum-free culture
medium once and then treated with or without recombinant human
epidermal growth factor (EGF) (Genzyme, Cambridge, MA,
USA) in the same culture medium. In this series of experiments,
A431 cells, human dermal fibroblasts and human epidermal
keratinocytes were used at the 11th–24th, 10th–22nd and 4th–8th
passage levels respectively.
Gelatin zymography
Gelatinolytic activity in culture media from the monolayer or the
co-culture was detected by gelatin zymography as described previ-
ously (Takahashi et al, 1991). Briefly, an aliquot (10 ml) of the
culture medium was subjected to sodium dodecyl sulphate-poly-
acrylamide gel electrophoresis (SDS-PAGE) using a 10% (w/v)
acrylamide gel containing 0.6 mg ml–1 of gelatin (DIFCO
Laboratories, Detroit, MI, USA). The gel was washed with
washing buffer (50 mM Tris–HCl (pH 7.5), 0.15 M sodium
chloride, 10 mM calcium chloride, 1 mM zinc chloride, 0.1% (v/v)
Triton X-100) to remove SDS and then incubated with incubation
buffer (50 mM Tris–HCl (pH 7.5), 0.15M sodium chloride, 10 mM
calcium chloride, 1 mM zinc chloride) for 6 h at 37°C. After incu-
bation, the gel was stained with Coomassie brilliant blue R-250
and gelatinolytic activity was detected as unstained bands on a
blue background.
Western blot analysis for MT1-MMP
To monitor the production of MT1-MMP, the cells were washed
with ice-cold PBS (–) once and then scraped into 50 mM Tris–HCl
(pH 7.4), 0.24 M sucrose with a rubber policeman. After centrifu-
gation at 180 g for 5 min at 4°C, the cells were resuspended in the
same buffer, sonicated six times at 4°C for 10 s and then
centrifuged at 500 g for 20 min at 4°C. The supernatant was
centrifuged at 100 000 g for 60 min. The subsequent precipitate
was resuspended in 50 mM Tris–HCl (pH 7.4) and then subjected
to Western blot analysis for detection of MT1-MMP. We
confirmed that MT1-MMP was not detected in the cytosolic frac-
tion. The protein concentration in the samples was determined
according to the method of Lowry et al (1951). A part (100 mg)
of the precipitate was mixed with SDS-PAGE sample buffer
including 2-mercaptoethanol (Laemmli, 1970) and then run on
10% (w/v) acrylamide gel. The proteins separated on the gel were
electrotransferred onto a nitrocellulose membrane. The membrane
was reacted with anti-MT1-MMP monoclonal antibody (114-1F2),
which was then complexed with alkaline phosphatase conjugated
rabbit anti-(mouse IgG)IgG. Immunoreactive MT1-MMP was
visualized with 5-bromo-4-chloro-3-indolyl phosphate and nitro
blue tetrazolium as described previously (Ito et al, 1998). The rela-
tive amounts of MT1-MMP were quantified by densitometric
scanning.
RNA isolation and Northern blot analysis
Total RNA was isolated from the co-culture of A431 cells and
fibroblasts or each monolayer culture by using ISOGEN (Nippon
Gene Co., Toyama, Japan) according to the protocol recommended
by the manufacturer. Isolated RNA (15 mg) was denatured and
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Figure 1 Augmentation of proMMP-2 activation in co-culture of A431 cells
and human dermal fibroblasts. (A) Confluent human dermal fibroblasts (Fib.)
at the 10th passage were co-cultured with A431 cells at the 18th passage at
the indicated cellular ratio for 24 h and then the cells were treated with or
without EGF (100 ng ml–1) for a further 24 h. In monolayer culture of A431
cells, the number of cells seeded corresponded to that for the cellular ratio of
4. (B) A431 cells at the 21st passage were seeded on confluent human
dermal fibroblasts (Fib.) at the 14th passage at the cellular ratio of 4 and the
co-culture was performed for 24 h. A431 cells were also cultured at the
number corresponding to the cellular ratio of 4 for 24 h. Those cells were
treated with or without EGF (1–100 ng ml–1) for a further 24 h. An aliquot
(10 ml) of the harvested culture medium was subjected to gelatin zymography
as described in Materials and Methods. Three independent experiments
were reproducible and typical data are shownelectrophoresed on 1.0% (w/v) agarose gel and then transferred
onto a nylon membrane (GeneScreen, DuPont, Boston, MA,
USA). The membrane was hybridized with cDNA probes for
MT1-MMP (1.5 kb) and human glyceraldehyde-3 phosphate
dehydrogenase (GAPDH) (1.1 kb, CLONTECH Laboratories,
Inc., Palo Alto, CA, USA) as described previously (Ito et al, 1998).
The relative amounts of steady-state MT1-MMP mRNA were
quantified by densitometric scanning and indicated after correction
for the GAPDH mRNA level.
Tumour invasion assay
Tumour invasion assay was performed using Matrigel Invasion
Chamber (Nippon Becton Dickinson Co. Ltd., Tokyo, Japan).
A431 cells and human fibroblasts were labelled with or without
5- and 6-carboxyfluorescein diacetate succinimidyl ester (CFSE)
(Dojindo Laboratories, Kumamoto, Japan) (Bronner-Fraser, 1985)
in 0.1% (w/v) bovine serum albumin–DMEM for 2 h. CFSE-
labelled human dermal fibroblasts and A431 cells were added into
the inserts together with CFSE-unlabelled A431 cells and human
dermal fibroblasts, respectively, with 4 ´ 104 cells (for A431 cells)
and 1 ´ 104 cells (for human fibroblasts). Following cell adhesion
for 1 h, the cells were treated with or without EGF (100 ng ml–1) in
the presence or the absence of recombinant human tissue inhibitor
of metalloproteinases 2 (TIMP-2) (a generous gift from Dr H
Nagase, University of Kansas Medical Center). After 48 h incuba-
tion, cells on the upper surface of the membrane were wiped with
a cotton swab and the number of fluoresced cells on the lower side
in ten randomly chosen areas per membrane was counted under a
fluorescent microscope at 200-fold magnification.
Immunostaining of MT1-MMP
Cultured A431 cells and/or human fibroblasts on chamber slides
(Nunc Inc., Naperville, IL, USA) were fixed for 1 h in freshly
prepared 4% (v/v) formaldehyde–PBS (–) and washed twice for
5 min with PBS (–). The fixed cells were treated with 0.3% (v/v)
hydrogen peroxide in MeOH for 1 h to quench endogenous peroxi-
dase, washed again with PBS (–) and then treated with 1.5% (v/v)
normal horse serum diluted in PBS (–) for 1 h to block non-specific
binding of the antibody. The cells were incubated with anti-MT1-
MMP monoclonal antibody (5 mg ml–1) overnight at 4°C. Non-
immune mouse IgG was utilized as a negative control for the primary
antibody. The cells were washed with PBS (–), stained by Vectastain
ABC Kit (Vector Laboratories, Inc., Burlingame, CA, USA).
Statistical analysis
Data were analysed by Student’s t-test; P < 0.05 was considered
statistically significant.
RESULTS
Activation of proMMP-2 by co-culture of A431 cells and
human fibroblasts
Human squamous carcinoma A431 cells were placed on a mono-
layer of confluent human dermal fibroblasts and then gelatin
zymography of the harvested culture media was performed. Figure
1A showed that fibroblasts spontaneously produced proMMP-2
but A431 cells did so poorly. The production of proMMP-2 was
unchanged by the co-culture as compared to that for the monolayer
culture of fibroblasts. When the cellular ratio of A431 cells to
fibroblasts was increased to 4, both 64-kDa intermediate and 62-
kDa active form of MMP-2 were increased. The proMMP-2 acti-
vation was observed with 1/4 cellular ratio of A431 (data not
shown) and significantly with 1-4 to human fibroblasts. These
results indicated that the cell–cell interaction of A431 cells and
fibroblasts resulted in the activation of proMMP-2, and that the
augmented proMMP-2 activation was dependent on the increase of
tumour cell number in co-culture.
EGF is known to participate in the tumorigenesis by augmenting
proliferation of carcinoma cells because those cells abundantly
express EGF receptor (Ozawa et al, 1987; Singletary et al, 1987).
In addition, Shima et al (1993) reported that the production of
proMMP-9 in oesophageal squamous carcinoma cells is
augmented by EGF. We therefore examined whether EGF could
modify the activation of proMMP-2 induced by co-culture of
A431 cells and fibroblasts. As shown in Figure 1A, the increased
activation of proMMP-2 by co-culture was enhanced by EGF-
treatment. The enhancement of proMMP-2 activation by EGF was
also dose-dependent with a notable effect at 10 ng ml–1 and the
maximum at 100 ng ml–1 (Figure 1B). These results suggest that
EGF may act as a promoter of the activation of proMMP-2
induced by co-culture of A431 cells and human fibroblasts.
Augmented proMMP-2 activation increases tumour
invasion in co-culture
To investigate whether the augmentation of proMMP-2 activation
causes the increase of tumour invasiveness in co-culture and
further characterize which cell line invades, tumour invasion assay
Enhancement of MT1-MMP production and proMMP-2 activation by co-culture 1139
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Figure 2 Preferential invasion of A431 cells in co-culture. CFSE-labelled
human dermal fibroblasts [Fib. (+)] at the 22nd passage and A431 cells
[A431 (+)] at the 24th passage were added into the inserts together with
CFSE-unlabelled A431 cells [A431 (–)] (A) and human dermal fibroblasts
[Fib. (–)] (B), respectively, and then treated with or without EGF (100 ng ml–1)
in the presence or the absence of TIMP-2 (100 ng ml–1) for 48 h as described
in Materials and Methods. The number of fluoresced cells on the lower side
in ten randomly chosen areas per membrane was counted under a
fluorescent microscope at 200-fold magnification. The data were indicated as
the mean ± s.d. of ten individual areas. Student’s t-test was used for analysis
of the data. ***, significantly differed from untreated co-culture (P < 0.001). a
and b, significantly differed from untreated and EGF-treated co-culture
respectively (P < 0.001). Lane 1, untreated co-culture; lane 2, EGF-treated
co-culture; lane 3, TIMP-2-treated co-culture; lane 4, EGF and TIMP-2-
treated co-culturewith a Matrigel model was performed. When A431 cells were
co-cultured with fluoresced human fibroblasts, there was little
number of fluorescence-positive cells detected regardless of the
presence or the absence of EGF (100 ng ml–1) (Figure 2A). On the
other hand, when fluoresced A431 cells were co-cultured with
human fibroblasts, the number of fluorescence-positive invaded
cells was significantly increased (Figure 2B) (1.9-fold increase as
compared with the fluoresced A431 cells alone, data not shown).
EGF further augmented the invasion of fluorescence-positive cells
in co-culture (1.8-fold), indicating that A431 cells but not human
fibroblasts in co-culture preferentially invaded through Matrigel.
In addition, the increased invasive activity of A431 cells was
inhibited by exogenously adding TIMP-2 (55 and 61% inhibition
in EGF-untreated and -treated co-culture, respectively). These
results suggest that the advanced proMMP-2 activation by co-
culture of A431 cells and human fibroblasts substantially increases
tumour invasiveness.
Human carcinoma cells but not normal human
keratinocytes augment proMMP-2 activation in human
fibroblasts
To examine whether the enhancement of proMMP-2 activation
was specifically caused by cell–cell interaction between tumour
cells and normal cells, the co-culture was performed with other
human squamous carcinoma cell lines, HSC-4 and SAS, and
normal human keratinocytes. As shown in Figure 3, no proMMP-
2 was detected in these carcinoma cells or human keratinocytes
(lane 5). Intense activation of proMMP-2 was observed in fibro-
blasts co-cultured with HSC-4 or SAS, but not with human normal
keratinocytes (lane 3). Unlike A431 cells, EGF (100 ng ml–1) did
not enhance the activation of proMMP-2 in the co-culture of HSC-
4 or SAS (lane 4) because proMMP-2 activation by the co-culture
was mostly completed. Therefore, we suggest that the augmenta-
tion of proMMP-2 activation is specifically occurred in the co-
culture of human squamous carcinoma cells and normal human
dermal fibroblasts.
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Figure 3 Activation of proMMP-2 by co-culture of human dermal fibroblasts
and human carcinoma cells or human keratinocytes. Confluent human
dermal fibroblasts at the 16th passage were co-cultured with HSC-4 (A), SAS
(B) or human keratinocytes at the 8th passage (C) at the cellular ratio of 4 for
24 h and then treated with or without EGF (100 ng ml–1) for a further 24 h. An
aliquot (10 ml) of the harvested culture medium was subjected to gelatin
zymography as described in Materials and Methods. Three independent
experiments were reproducible and typical data are shown. Lanes 1 and 2,
fibroblasts alone; lanes 3 and 4, fibroblasts co-cultured with HSC-4, SAS or
keratinocytes; lanes 5 and 6, HSC-4, SAS or keratinocytes alone. Cells in
lanes 2, 4 and 6 were also treated with EGF (100 ng ml–1)
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Figure 4 Induction of MT1-MMP production in co-culture of A431 cells and
human dermal fibroblasts. Confluent human dermal fibroblasts at the 13th
passage were co-cultured with A431 cells at the 15th passage at the cellular
ratio of 4 for 24 h. In monolayer culture of A431 cells, the number of cells
seeded corresponded to that for the cellular ratio of 4. Those cells were
treated with or without EGF (100 ng ml–1) for another 24 h. The harvested
culture medium and membrane fractions were subjected to gelatin
zymography (A) and Western blot analysis (B), respectively, as described in
Materials and Methods. The relative production of MT1-MMP was quantified
by densitometric scanning and taking the control value of 1 in A431 cells
alone (C). Three independent experiments were reproducible and typical
data are shown. Lanes 1 and 2, fibroblasts alone; lanes 3 and 4, fibroblasts
co-cultured with A431 cells; lanes 5 and 6, A431 cells alone. Cells in lanes 2,
4 and 6 were also treated with EGF (100 ng ml–1)
Figure 5 Induction of MT1-MMP mRNA expression in co-culture of A431
cells and human dermal fibroblasts. Total RNA (15 mg) was subjected to
Northern blot analysis as described in Materials and Methods. (A) MT1-MMP
mRNA and (B) GAPDH mRNA. The relative amount of MT1-MMP mRNA
was quantified by densitometric scanning and taking the control value of 1 in
human dermal fibroblasts by standardizing with that of GAPDH mRNA (C).
Three independent experiments were reproducible and typical data are
shown. Lanes 1 and 2, fibroblasts alone; lanes 3 and 4, fibroblasts co-
cultured with A431 cells; lanes 5 and 6, A431 cells alone. Cells in lanes 2, 4
and 6 were treated with EGF (100 ng ml–1)
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ACo-culture induces the production of MT1-MMP along
with the augmentation of its gene expression
Next we investigated whether the augmentation of proMMP-2
activation was related to an increase in the production of MT1-
MMP. Although MT1-MMP was not detected in fibroblasts and
only slightly in A431 cells, the co-culture enhanced MT1-MMP
production (Figure 4B, lane 3; 4.3-fold vs A431 cell alone) with
consequent activation of proMMP-2 (Figure 4A, lane 3). Northern
blot analysis (Figure 5) also indicated that cell–cell interaction
enhanced the expression of MT1-MMP mRNA as compared to
that for fibroblasts and A431 cells (5.8-fold and 19.3-fold, respec-
tively). A similar increase in MT1-MMP mRNA was observed in
fibroblasts cultured with HSC-4 or SAS (data not shown), indi-
cating that the augmentation of MT1-MMP production by co-
culture resulted from increasing its gene expression. On the other
hand, EGF further augmented the co-culture-mediated production
of MT1-MMP and its mRNA (1.2- and 1.4-fold, respectively) and
concomitantly enhanced proMMP-2 activation (Figures 4 and 5,
lane 4). These results suggest that EGF augments the production of
MT1-MMP, and thereby the activation of proMMP-2 is increased
in the co-culture of A431 cells and human dermal fibroblasts.
Increased production of MT1-MMP in A431 cells, but
not in human fibroblasts of co-culture
We further characterized which cell line expressed MT1-MMP
when A431 cells and fibroblasts were co-cultured. As shown in
Figure 6A, the expression of MT1-MMP was significantly
augmented in A431 cells, but not in human fibroblasts in the co-
culture. By contrast, when the cells were stained by non-immune
mouse IgG, the signals of MT1-MMP were no longer detected in
A431 cells in the co-culture (Figure 6B). On the other hand, MT1-
MMP was not detected in either monolayer culture of A431 cells
or human fibroblasts (Figure 6C and D, respectively). These
results indicated that MT1-MMP in tumour cells was preferen-
tially produced by cell–cell interaction and suggested that the
sequential activation of proMMP-2 by MT1-MMP may progress
on the tumour cell surface.
DISCUSSION
The increased production of proMMP-2 is known to relate to
tumour invasiveness both in vivo and in vitro (Pyke et al, 1992;
Stearns and Wang, 1993; Stetler-Stevenson et al, 1993). Azzam et
Enhancement of MT1-MMP production and proMMP-2 activation by co-culture 1141
British Journal of Cancer (1999) 80(8), 1137–1143 © 1999 Cancer Research Campaign 
AB
CD
Figure 6 The production of MT1-MMP is augmented in co-cultured A431 cells, but not fibroblasts. Human dermal fibroblasts at the 19th passage were co-
cultured with A431 cells at the 20th passage at the cellular ratio of 4 for 24 h. (A and B) Co-culture stained with monoclonal anti-(human MT1-MMP) antibody
and non-immune mouse IgG, respectively. (C and D) A431 cells and human dermal fibroblasts stained with monoclonal anti-(human MT1-MMP) antibody,
respectively. Closed and open arrows in Panels A and B indicate A431 cells and fibroblasts respectivelyal (1993) reported that increased activation of proMMP-2 is
restricted to highly invasive human breast cancer cells, but it is not
fully understood how the activation of proMMP-2 is accomplished
in cancer cells or tissue. In the present study, we demonstrated that
human squamous carcinoma cells interacted with normal human
fibroblasts augmented the activation of proMMP-2, whereas
normal human keratinocytes did not, and further that tumour cells
in the co-culture preferentially invaded through Matrigel in in
vitro tumour invasion assay system. These observations propose
an in vivo mechanism in which the increased activity of MMP-2
associated with tumour invasiveness is evoked by the cell–cell
interaction between the grown tumour cells and the surrounding
normal cells.
MT-MMPs have been cloned and characterized as a specific
proMMP-2 activator. Sato et al (1994) demonstrated that MT1-
MMP overexpressed in HT-1080 cells and NIH3T3 cells converts
72-kDa proMMP-2 into a 62-kDa active form, which is correlated
with in vitro invasiveness of those cells. Pei and Weiss (1996)
reported that a soluble mutant of MT1-MMP deleting the transmem-
brane domain proteolytically converts proMMP-2 to the active
form. Since many investigators have focused on the molecular
mechanism of proMMP-2 activation by MT-MMPs, there is little
evidence concerning the regulation of MT-MMP production. Lohi et
al (1996) reported that phorbol ester transcriptionally induces the
production of MT1-MMP in HT-1080 cells and human fibroblasts.
Our present study showed that co-culture of A431 cells and human
fibroblasts increased the production of MT1-MMP together with the
augmentation of its mRNA level. A similar increase in MT1-MMP
mRNA was observed in other types of carcinoma cells, HSC-4 and
SAS co-cultured with human fibroblasts (data not shown). Thus,
these results provide strong evidence that cell–cell interaction
between carcinoma and normal stroma cells has the initiative in
increasing the production of MT1-MMP.
Recent studies have shown the mechanism by which cell–cell
interaction influences proMMPs expression in various cell types.
Ito et al (1995) reported that breast adenocarcinoma MCF-7 cell-
derived membrane bound factor together with the soluble one
augments the production of proMMPs-1 and -3 and their inhibitor
TIMP-1 in neighbouring stroma cells. Westerlund et al (1997) also
reported that normal fibroblasts stimulate human ovarian cancer
cells to increase their invasiveness and MMP-2 production in an
autocrine and paracrine manner. We, however, demonstrated that
both the membrane fraction and conditioned medium of A431
cells or fibroblasts modify neither the activation of proMMP-2 nor
its production in each monolayer culture (data not shown). This
result suggests that both A431 cells and human dermal fibroblasts
in the monolayer culture do not produce any factors for increasing
the activation of proMMP-2. Alternatively, it is possible that
factor(s) expressed substantially in the co-culture condition partic-
ipates in augmenting the activation of proMMP-2 as well as the
production of MT1-MMP, although a principal mechanism by
which proMMP-2 activation and MT1-MMP production are
enhanced in this co-culture system tested remains unclear.
It has been reported that in host fibroblasts the gene expression
of MT1-MMP is enhanced by soluble factor(s) secreted by inva-
sive breast tumour cells and thereby the activation of proMMP-2 is
occurred on the cell surface of fibroblasts (Polette et al, 1997). In
contrast, our result by immunohistochemistry showed that MT1-
MMP production in the co-culture was augmented predominantly
in A431 cells but not in human fibroblasts, suggesting that the
increase of proMMP-2 activation occurs on the tumour cell
surface. In regard of the different observation, we postulate that
proMMP-2 activation which is accomplished on the cell surface of
either tumour or adjacent stroma cells may be dependent on the
tumour cell type.
Our results showed that EGF further enhanced the activation of
proMMP-2 in co-culture of A431 cells and fibroblasts. We also
demonstrated that EGF induced the predominant invasion of A431
cells in the co-culture and the increased invasive activity was
inhibited by exogenously adding TIMP-2. Taken together with our
immunohistochemical evidence (Figure 6) and a previous paper
(Singletary et al, 1987) these results suggest that in human carci-
nomas, at least A431 cells, EGF is very likely to be an enhancer
of tumour invasiveness by increasing proMMP-2 activation on
tumour cell surface.
We observed discrepancies in that the extent of proMMP-2 acti-
vation by the co-culture was low although the induction of MT1-
MMP was quite high, and that EGF relatively elicited a slight
enhancement of MT1-MMP gene and protein levels, but appar-
ently augmented the activation of proMMP-2 as compared to the
EGF-untreated co-culture. Concerning these points, recent studies
indicating that TIMP-2 participates in the regulation of proMMP-2
activation by MT1-MMP are of particular interest. Will et al
(1996) and Kinoshita et al (1996) reported that TIMP-2 preferen-
tially inhibits MT1-MMP activity to decrease proMMP-2 activa-
tion. On the other hand, TIMP-2 has been shown to promote
proMMP-2 activation by MT1-MMP (Strongin et al, 1995;
Kinoshita et al, 1998). We preliminarily demonstrated that the
production of TIMP-2 was increased by the co-culture and EGF
decreased the augmented TIMP-2 production (T Sato et al, un-
published data). Thus, we speculate that the increased TIMP-2
production in co-culture may suppress the activation of proMMP-
2 by MT1-MMP even though MT1-MMP production is
augmented, and that the down-regulation of TIMP-2 production
by EGF may subsequently accelerate the proMMP-2 activation in
the co-culture. Otherwise, it is suggested that EGF may promote
the TIMP-2-mediated ternary complex formation with MT1-MMP
and proMMP-2 on cell surface to accomplish proMMP-2 activa-
tion in the co-culture. Further experiments will be required for
addressing the involvement of TIMP-2 in MT1-MMP-mediated
proMMP-2 activation in this co-culture system.
In conclusion, we demonstrated that direct attachment of carci-
noma cells to human fibroblasts augments the production of MT1-
MMP and consequently activates proMMP-2 on the tumour cell
surface. Therefore, this possible mechanism plays an important
role in the tumour invasion in vivo by increasing proteolytic
activity to degrade extracellular matrices at the tumour–stroma
junction.
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